Enlivex Ltd. (ENLV)
0.277
-0.03
(-9.60%)
USD |
NASDAQ |
Oct 08, 16:00
0.2553
-0.02
(-7.83%)
After-Hours: 07:39
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.662M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -98.42% |
| Valuation | |
| PE Ratio | 0.0006 |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 0.0012 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0045 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.67% |
Profile
| Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel. |
| URL | http://www.enlivex.com |
| Investor Relations URL | https://investors.enlivex.com/ |
| HQ State/Province | Tel Aviv |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 18, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel. |
| URL | http://www.enlivex.com |
| Investor Relations URL | https://investors.enlivex.com/ |
| HQ State/Province | Tel Aviv |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 18, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |